Evidence map›Paper›PMID 37641004›Full record

ArticleBMC cancer2023

The antitumor effect of oncolytic respiratory syncytial virus via the tumor necrosis factor-alpha induction and ROS-bax-mediated mechanisms.

Mehdi Samadi, Talat Mokhtari-Azad, Ahmad Nejati, Zahra Norooz-Babaei, Abbas Rahimi Foroushani, Mohammad Reza Haghshenas, Fatemeh Adjaminejad, Hedieh Zargaran, Vahid Salimi, Amir Ghaemi

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Mehdi SamadiVirology Department, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Talat Mokhtari-AzadVirology Department, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Ahmad NejatiVirology Department, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Zahra Norooz-BabaeiVirology Department, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Abbas Rahimi ForoushaniDepartment of Statistics and Epidemiology, School of Public Health, Tehran University of medical sciences, Tehran, Iran.
Mohammad Reza HaghshenasDepartment of Microbiology, Molecular, and Cell-Biology Research Center, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
Fatemeh AdjaminejadVirology Department, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Hedieh ZargaranDepartment of Influenza and Other Respiratory Viruses, Pasteur Institute of Iran, Tehran, Iran.
Vahid SalimiVirology Department, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran. vahidsalimii@gmail.com.
Amir GhaemiDepartment of Influenza and Other Respiratory Viruses, Pasteur Institute of Iran, Tehran, Iran. ghaem_amir@yahoo.com.
Tehran University of Medical Sciences · IRPasteur Institute of Iran · IRMazandaran University of Medical Sciences · IR

Funding

Tehran University of Medical Sciences and Health Services 99-1-99-42374
6 · The paper itself

Abstract

backgroundCervical cancer represents one of the most prevalent cancers among women worldwide, particularly in low- and middle-income nations. Oncolytic viruses (OVs) can infect cancer cells selectively and lethally without harming normal cells. Respiratory syncytial virus (RSV) is an oncolytic virus for anticancer therapy because of its propensity to multiply within tumor cells. This research aimed to assess the in vitro antitumor activities and molecular basis processes of the oncolytic RSV-A2 on the TC-1 cancer cells as a model for HPV‑related cervical cancers.

methodsCellular proliferation (MTT) and lactate dehydrogenase (LDH) release assays were used to investigate the catalytic impacts of RSV-A2 by the ELISA method. Real-time PCR and flow cytometry assays were utilized to assess apoptosis, autophagy, intracellular concentrations of reactive oxygen species (ROS), and cell cycle inhibition.

resultsOur MTT and LDH results demonstrated that TC-1 cell viability after oncolytic RSV-A2 treatment was MOI-dependently and altered significantly with increasing RSV-A2 virus multiplicity of infection (MOI). Other findings showed that the RSV-A2 potentially resulted in apoptosis and autophagy induction, caspase-3 activation, ROS generation, and cell cycle inhibition in the TC-1 cell line. Real-time PCR assay revealed that RSV-A2 infection significantly elevated the Bax and decreased the Bcl2 expression.

conclusionsThe results indicated that oncolytic RSV-A2 has cytotoxic and inhibiting effects on HPV-associated cervical cancer cells. Our findings revealed that RSV-A2 is a promising treatment candidate for cervical cancer.

Indexed as

Papillomavirus InfectionsUterine Cervical Neoplasmsbcl-2-Associated X ProteinFemaleHumansReactive Oxygen SpeciesRespiratory Syncytial VirusesTumor Necrosis Factor-alphabcl-2-Associated X ProteinReactive Oxygen SpeciesTumor Necrosis Factor-alphaApoptosisAutophagyHuman papillomavirusHuman respiratory syncytial virusOncolytic virusesReactive oxygen species

Identifiers

PMID37641004
PMCPMC10464077
OpenAlexW4386225230

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.